Zogenix completes enrollment in phase 3 trial of FINTEPLA® in Lennox-Gastaut syndrome
Zogenix announced it has completed enrollment for, and randomized the last patient into the treatment period of, Study 1601, the Company’s Phase 3 clinical trial of its lead investigational therapy, FINTEPLA® (ZX008, fenfluramine), for treatment of seizures associated with Lennox-Gastaut Syndrome. July 08, 2019